Lantern Pharma Q1 2024 GAAP EPS $(0.51) Misses $(0.43) Estimate
Portfolio Pulse from Benzinga Newsdesk
Lantern Pharma reported a Q1 2024 GAAP EPS loss of $(0.51), missing the $(0.43) estimate, marking an 18.6% miss and a 41.67% increase in losses from the same period last year.

May 09, 2024 | 9:02 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Lantern Pharma's Q1 2024 earnings report showed a significant miss on EPS estimates and a substantial increase in losses compared to last year.
Missing earnings estimates, especially by a significant margin such as 18.6%, typically leads to negative investor sentiment and can cause a short-term decline in stock price. The reported increase in losses from the previous year further compounds the negative outlook, suggesting operational or market challenges.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100